Pharmaceutical intermediates
Milvexian Intermediates
6 pharmaceutical intermediates for Milvexian. Indication: Reduce the risk of Thrombosis, Ischemic Stroke, Atrial Fibrillation, Acute Coronary Syndrome (ACS).
About Milvexian
- Originator
- Bristol Myers Squibb
- Indication
- Reduce the risk of Thrombosis, Ischemic Stroke, Atrial Fibrillation, Acute Coronary Syndrome (ACS)
Available intermediates
6 intermediates currently listed for Milvexian. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (R)-2-methylbut-3-enoic acid | 20626-49-7 | / | / |
| (5R,9S)-9-amino-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclononaphan-4-one | 1802431-24-8 | / | / |
| 6-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)pyrimidin-4-ol | 1802430-55-2 | / | / |
| Pyrimidine, 4-[5-chloro-2-[4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl]phenyl]-6-methoxy- | 1802430-53-0 | / | / |
| Pyrimidine, 4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-methoxy- | 1802430-54-1 | / | / |
| tert-butyl(S)-(1-(4-chloropyridin-2-yl)but-3-en-1-yl)carbamate | 1329171-69-8 | / | / |
Building toward Milvexian?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →